Second-Line, Biomarker-Driven Therapies for Squamous NSCLC: Report on Lung-MAP SWOG S1400

China’s Domestic PD-1/PD-L1 Inhibitors Demanding Global Attention

Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC

NCI Launches the Cancer Moonshot SM Biobank to Accelerate Research in Cancer Treatment

Voice from Asia: Combination of Immune Checkpoint Inhibitors With Chemotherapy for Advanced Non-squamous NSCLC

ASCO and Ontario Health Publish Joint Guideline Update on Systemic Therapy for Stage IV NSCLC

Immunotherapy Use in Patients With Lung Cancer and Comorbidities

Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)

Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team

COVID-19 and Lung Cancer: A Call for Immediate Action

A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC

Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks